Show simple item record

dc.contributor.authorBarrasa, Helena
dc.contributor.authorSoraluce Olañeta, Amaia
dc.contributor.authorUsón, Elena
dc.contributor.authorSainz, Javier
dc.contributor.authorMartín, Alejandro
dc.contributor.authorSánchez Izquierdo, José Ángel
dc.contributor.authorMaynar, Javier
dc.contributor.authorRodríguez Gascón, Alicia
dc.contributor.authorIsla Ruiz, Arantxazu
dc.date.accessioned2020-06-05T10:25:28Z
dc.date.available2020-06-05T10:25:28Z
dc.date.issued2020-04
dc.identifier.citationInternational Journal of Infectious Diseases 93 : 329-338 (2020)es_ES
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.urihttp://hdl.handle.net/10810/43838
dc.description.abstractObjectives: The aim of this study was to assess the influence of renal function, in particular the presence of augmented renal clearance (ARC), on the pharmacokinetics of linezolid in critically ill patients. The effect of continuous infusion on the probability of therapeutic success from a pharmacokinetic/pharmacodynamic (PK/PD) perspective was also evaluated. Methods: Seventeen patients received linezolid (600 mg every 12 h) as a 30-min infusion and 26 as a continuous infusion (50 mg/h). The PK parameters were calculated and the probability of PK/PD target attainment (PTA) was estimated by Monte Carlo simulation (MCS) for different doses administered by intermittent (600 mg every 12 h or 600 mg every 8 h) or continuous infusion (50 mg/h or 75 mg/h). Results: In patients without ARC, the standard dose was adequate to attain the PK/PD target. However, linezolid clearance was significantly higher in ARC patients, leading to sub-therapeutic concentrations. Continuous infusion (50 mg/h) provided concentrations >= 2 mg/l in 70% of the ARC patients. MCS revealed that concentrations >= 2 mg/l would be reached in >90% of patients receiving 75 mg/h. Conclusions: ARC increases linezolid clearance and leads to a high risk of underexposure with the standard dose. Continuous infusion increases the PTA, but an infusion rate of 75 mg/h should be considered to ensure concentrations >= 2 mg/ml.es_ES
dc.description.sponsorshipThis work was supported by the University of the Basque Country UPV/EHU (PPG17/65, GIU17/32), Spain.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectlinezolides_ES
dc.subjectaugmented renal clearancees_ES
dc.subjectpharmacokinetic/pharmacodynamicses_ES
dc.subjectcritically ill patientses_ES
dc.subjectcontinuous infusiones_ES
dc.subjectpharmacodynamicses_ES
dc.subjectplasmaes_ES
dc.subjectvancomycines_ES
dc.subjecttherapyes_ES
dc.subjectprofilees_ES
dc.subjectfluides_ES
dc.titleImpact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspectivees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.clinicalkey.es/#!/content/playContent/1-s2.0-S1201971220301028?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1201971220301028%3Fshowall%3Dtrue&referrer=es_ES
dc.identifier.doi10.1016/j.ijid.2020.02.044
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).